Compare LXEO & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LXEO | EAD |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.5M | 377.0M |
| IPO Year | 2023 | N/A |
| Metric | LXEO | EAD |
|---|---|---|
| Price | $4.88 | $6.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $18.44 | N/A |
| AVG Volume (30 Days) | ★ 910.6K | 294.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.91% |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $6.24 |
| 52 Week High | $10.99 | $7.15 |
| Indicator | LXEO | EAD |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 44.42 |
| Support Level | $4.39 | $6.24 |
| Resistance Level | $5.01 | $6.45 |
| Average True Range (ATR) | 0.31 | 0.04 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 54.39 | 12.50 |
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Allspring Income Opportunities Fund is a diversified closed-end management investment company. The Fund seeks a high level of current income. Capital appreciation is a secondary objective. The fund has single operating segment.